Latest news with #Omnicell
Yahoo
2 days ago
- Business
- Yahoo
What To Expect From Premier's (PINC) Q2 Earnings
Healthcare tech company Premier (NASDAQ:PINC) will be reporting earnings this Tuesday morning. Here's what you need to know. Premier beat analysts' revenue expectations by 7.4% last quarter, reporting revenues of $261.4 million, down 8.9% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' full-year EPS guidance estimates. Is Premier a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Premier's revenue to decline 28.5% year on year to $250.4 million, a reversal from the 2.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.34 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Premier has missed Wall Street's revenue estimates four times over the last two years. Looking at Premier's peers in the healthcare technology for providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Privia Health delivered year-on-year revenue growth of 23.4%, beating analysts' expectations by 10.9%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Privia Health traded up 4% following the results while Omnicell's stock price was unchanged. Read our full analysis of Privia Health's results here and Omnicell's results here. There has been positive sentiment among investors in the healthcare technology for providers segment, with share prices up 7.2% on average over the last month. Premier is up 19.2% during the same time and is heading into earnings with an average analyst price target of $22.33 (compared to the current share price of $24.95). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
06-08-2025
- Business
- Yahoo
Evolent Health (EVH) Q2 Earnings Report Preview: What To Look For
Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting results this Thursday after the bell. Here's what investors should know. Evolent Health beat analysts' revenue expectations by 4.9% last quarter, reporting revenues of $483.6 million, down 24.4% year on year. It was a mixed quarter for the company, with full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Evolent Health's revenue to decline 29% year on year to $459.5 million, a reversal from the 37.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.08 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street's revenue estimates twice over the last two years. Looking at Evolent Health's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 5%, beating analysts' expectations by 4.9%, and Hims & Hers Health reported revenues up 72.6%, falling short of estimates by 1.1%. Omnicell's stock price was unchanged after the resultswhile Hims & Hers Health was down 12.5%. Read our full analysis of Omnicell's results here and Hims & Hers Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Evolent Health is down 18.4% during the same time and is heading into earnings with an average analyst price target of $15.31 (compared to the current share price of $9.50). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
05-08-2025
- Business
- Yahoo
GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Wednesday after the bell. Here's what to expect. GoodRx met analysts' revenue expectations last quarter, reporting revenues of $203 million, up 2.6% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and a significant miss of analysts' customer base estimates. It lost -200,000 customers and ended up with a total of 6.4 million. Is GoodRx a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting GoodRx's revenue to grow 2.5% year on year to $205.7 million, slowing from the 5.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.10 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GoodRx has missed Wall Street's revenue estimates twice over the last two years. Looking at GoodRx's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts' expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell's stock price was unchanged following the results. Read our full analysis of Hims & Hers Health's results here and Omnicell's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. GoodRx is down 4.6% during the same time and is heading into earnings with an average analyst price target of $6.32 (compared to the current share price of $4.52). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-08-2025
- Business
- Yahoo
Tandem Diabetes (TNDM) Q2 Earnings Report Preview: What To Look For
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings this Wednesday after the bell. Here's what investors should know. Tandem Diabetes beat analysts' revenue expectations by 6.8% last quarter, reporting revenues of $234.4 million, up 22.3% year on year. It was a strong quarter for the company, with an impressive beat of analysts' sales volume estimates and full-year revenue guidance meeting analysts' expectations. Is Tandem Diabetes a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Tandem Diabetes's revenue to grow 6.8% year on year to $237.1 million, slowing from the 13.3% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.40 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tandem Diabetes has missed Wall Street's revenue estimates three times over the last two years. Looking at Tandem Diabetes's peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hims & Hers Health delivered year-on-year revenue growth of 72.6%, missing analysts' expectations by 1.1%, and Omnicell reported revenues up 5%, topping estimates by 4.9%. Omnicell's stock price was unchanged following the results. Read our full analysis of Hims & Hers Health's results here and Omnicell's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Tandem Diabetes is down 5.1% during the same time and is heading into earnings with an average analyst price target of $31.10 (compared to the current share price of $15.42). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-08-2025
- Business
- Yahoo
What To Expect From Hims & Hers Health's (HIMS) Q2 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after market hours. Here's what to expect. Hims & Hers Health beat analysts' revenue expectations by 8.3% last quarter, reporting revenues of $586 million, up 111% year on year. It was a strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year EBITDA guidance beating analysts' expectations. It added 137,000 customers to reach a total of 2.37 million. Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hims & Hers Health's revenue to grow 74.5% year on year to $550.8 million, improving from the 51.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.2% on average. Looking at Hims & Hers Health's peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts' revenue estimates by 4.9%, delivering year-on-year sales growth of 5%. The stock price was unchanged following the results. Read our full analysis of Omnicell's earnings results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Hims & Hers Health is up 29% during the same time and is heading into earnings with an average analyst price target of $48.36 (compared to the current share price of $62.48). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
